Hongtao Lu

Title: Hongtao Lu: Innovator in Antibody Research

Introduction

Hongtao Lu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibody therapies. With a total of 2 patents, his work focuses on advancing medical treatments through targeted therapies.

Latest Patents

Hongtao Lu's latest patents include groundbreaking research on anti-CD39 antibodies. This patent provides anti-CD39 antibodies or antigen-binding fragments, along with isolated polynucleotides encoding these antibodies, pharmaceutical compositions, and their various uses. Another notable patent involves a CD47 antigen binding unit, which specifically binds to CD47. This patent also discloses polynucleic acids encoding the antigen binding units, vectors containing these polynucleic acids, and methods for inducing phagocytosis of CD47-expressing cells.

Career Highlights

Throughout his career, Hongtao Lu has worked with several notable companies in the biopharmaceutical sector. He has been associated with Elpiscience Biopharma, Ltd and Zlip Holding Limited, where he has contributed to the advancement of innovative therapies.

Collaborations

Hongtao Lu has collaborated with esteemed colleagues, including Yangsheng Qiu and Meiling Sun, to further enhance his research and development efforts.

Conclusion

Hongtao Lu's contributions to antibody research and his innovative patents highlight his role as a key figure in the biopharmaceutical industry. His work continues to pave the way for new therapeutic options in medicine.